THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.
"The data being presented at the 2011 European Multidisciplinary Cancer Congress reflect Amgen's ongoing commitment to advancing the understanding of cancer and developing novel therapies to treat it," said Willard H. Dere, M.D., senior vice president and international chief medical officer at Amgen. "New biomarker analyses for Vectibix reinforce the importance of patient selection when EGFR inhibitors are used in metastatic colorectal cancer, while data from the '147 study demonstrate the potential for XGEVA to be the first treatment to prevent the spread of prostate cancer to the bone."
SELECTED ABSTRACTS OF INTERESTIdentified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.
Denosumab and Bone Metastasis-free Survival in Men with Castrate-resistant Prostate Cancer: Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial(Abstract 7003) Proffered Papers Session Genitourinary Malignancies – Prostate Cancer on Sunday, Sept. 25, 9:45 a.m. CEST, Hall A3 Data embargoed until 12:01 a.m. CEST on Sept. 24. Data to be highlighted in EMCC press program on Sept. 24 at 8:00 a.m. CEST, Room K21 (Level 1).
Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results from a Phase 2 Study(Abstract 32LBA) Proffered Papers Session, Sarcoma on Tuesday, Sept. 27, 11:00 a.m. CEST, Hall T2
Pain Outcomes in a Randomized Phase 3 Clinical Trial of Denosumab vs
Copyright©2010 PR Newswire.
All rights reserved